Novo Nordisk's US-listed shares close at an all-time high of $135.66

Novo Nordisk's American depositary receipts closed at $135.66 on June 25, 2024, the highest closing price in the company's history on the US market ^[1]. That day marked the top of a multi-year climb driven by the maker of semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management ^[1]. It also marked a turning point: the shares fell for more than two years afterward.

How big the run was

The share price data, adjusted for splits and dividends, shows three straight years of large gains before the peak. Novo Nordisk's US listing rose 63.52% in 2021, 22.66% in 2022 and 54.84% in 2023 ^[1]. The stock closed 2021 at $49.94 and 2022 at $61.25, then finished 2023 at $94.85 ^[1]. From the end of 2021 to the June 2024 record, the price nearly tripled ^[1].

The reversal was just as steep. Novo Nordisk's shares ended 2024 at $79.73, down 15.94% for the year despite having set the all-time high in June ^[1]. In 2025 the stock fell another 39.22%, closing the year at $48.46 after opening at $81.12 ^[1]. As of September 14, 2026, the most recent close in the data was $43.45, down 10.34% for the year to date ^[1]. Over the prior 52 weeks the shares traded between $35.12 and $64.16, averaging $47.75 ^[1].

The scale of the decline is easier to see in company size. Macrotrends lists Novo Nordisk's market capitalization at $192.308 billion against revenue of $46.797 billion ^[1]. By comparison, Eli Lilly — the maker of tirzepatide, sold as Mounjaro and Zepbound — carries a market value of $1.050 trillion in the same data set ^[1].

The sources here cover share prices and company size only. They do not explain what caused the peak or the subsequent decline, and they contain no information about drug pricing, supply, clinical trial results or regulatory decisions. Those causes are not established by the available material.

Why it matters for patients

A stock price is not a price tag on a prescription, and nothing in this data says anything about what a patient pays at the pharmacy. But share prices do reflect what investors expect a company to earn, and Novo Nordisk's business is heavily concentrated in the products many GLP-1 patients use. The company describes itself as a leader in the global diabetes market and operates through two segments, one covering insulins, GLP-1 medicines, obesity treatments and oral diabetes drugs, and the other covering hemophilia, growth hormone and hormone replacement therapy ^[1]. Its best-known products include Ozempic, Rybelsus, Saxenda and Victoza ^[1]. Novo Nordisk launched its first weight-management product, Saxenda, in the United States in 2015 ^[1].

When a company that large loses roughly two-thirds of its market value from its peak, it usually signals that investors have lowered their expectations about future sales, competition or margins in that business ^[1]. For patients, the practical relevance is indirect: financial pressure can influence how manufacturers set list prices, fund patient assistance, invest in manufacturing capacity and decide which programs to continue. None of those specific effects is described in the sources, so they remain unknown here.

The gap between Novo Nordisk's and Eli Lilly's market values is also a rough measure of how investors now view the competitive balance between semaglutide and tirzepatide products ^[1]. That is a market judgment, not a clinical one. It says nothing about which medicine works better for any individual.

What happens next

The data set runs through September 14, 2026, when the shares closed at $43.45 ^[1]. Whether the decline continues depends on company results and competitive developments that are not covered in these sources. Patients tracking the companies behind their medications may find quarterly earnings reports and regulatory announcements more informative than daily share moves, since those filings contain the sales, supply and pipeline details that share prices only summarize.